Bradley Merrill Thompson, Member of the Firm in the Health Care & Life Sciences practice, in the firm’s Washington, DC, office, was quoted in Medtech Dive, in “FDA Greenlights Expanded Remote Patient Monitoring to Keep Patients Out of Coronavirus-Slammed Hospitals,” by Susan Kelly.

Following is an excerpt:

FDA on Friday issued a policy to facilitate greater use of remote patient monitoring technologies to cut back on hospital visits and thereby minimize risk of exposure to COVID-19 while also reducing the burden on providers during the current crisis. …

The guidance document is one of several FDA has issued responding to COVID-19 in recent weeks. Others this week covered hand sanitizer preparation, conducting clinical trials during the pandemic, and new parameters for rapidly increasing diagnostic testing capacity.

The remote patient monitoring device guidance applies to non-invasive devices that can be connected to a wireless network through Bluetooth, Wi-Fi or cellular connection to transmit a patient’s measurements directly to their healthcare provider or other monitoring entity. Some of the devices have the potential to apply algorithms to turn a patient’s physiological data into an index or alarm that may aid in diagnosing or assessing the severity of a condition.​

In making way for an increase in remote monitoring, FDA is waiving a limitation on clinical decision support (CDS) software to now allow for the development of products that can provide advice on diagnosing and treating the coronavirus, Epstein Becker & Green attorney Bradley Thompson said in comments shared with MedTech Dive.

In September, the agency published a revised draft guidance detailing plans for regulating CDS software that reflected industry feedback seeking a risk-based approach for the software, but which some argued did not go far enough. At the time, FDA indicated it would exempt from regulation software that is low risk, and focus oversight on technology that supports clinical management for serious conditions in which a healthcare professional cannot independently evaluate the basis of software recommendations.

“What FDA is doing in this emergency guidance is basically waving that September 2019 objection that CDS can only escape FDA regulation if it is both low risk and transparent. FDA is saying in this context, even though the risk is arguably higher, they will accept transparency. That’s a really good thing,” Thompson said in an email. Thompson is also part of the CDS Coalition, which advocates against over-regulation of clinical decision support software.

Jump to Page

Privacy Preference Center

When you visit any website, it may store or retrieve information on your browser, mostly in the form of cookies. This information might be about you, your preferences or your device and is mostly used to make the site work as you expect it to. The information does not usually directly identify you, but it can give you a more personalized web experience. Because we respect your right to privacy, you can choose not to allow some types of cookies. Click on the different category headings to find out more and change our default settings. However, blocking some types of cookies may impact your experience of the site and the services we are able to offer.

Strictly Necessary Cookies

These cookies are necessary for the website to function and cannot be switched off in our systems. They are usually only set in response to actions made by you which amount to a request for services, such as setting your privacy preferences, logging in or filling in forms. You can set your browser to block or alert you about these cookies, but some parts of the site will not then work. These cookies do not store any personally identifiable information.

Performance Cookies

These cookies allow us to count visits and traffic sources so we can measure and improve the performance of our site. They help us to know which pages are the most and least popular and see how visitors move around the site. All information these cookies collect is aggregated and therefore anonymous. If you do not allow these cookies we will not know when you have visited our site, and will not be able to monitor its performance.